Advanced solid tumor Trials in Heidelberg, Australia
Conditions / Advanced solid tumor / Heidelberg, Australia
Advanced solid tumor has been the subject of sustained clinical investigation across multiple research sites.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | COMPLETED | PHASE1/PHASE2 |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | RECRUITING | — |
| NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | TERMINATED | PHASE1 |
| NCT06589596 | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | UNKNOWN | PHASE1 |